MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms

dc.contributor.authorSoldevilla Navarro, Beatriz
dc.contributor.authorLens Pardo, Alberto
dc.contributor.authorEspinosa Olarte, Paula
dc.contributor.authorCarretero Puche, Carlos
dc.contributor.authorMolina Pinelo, Sonia
dc.contributor.authorRobles, Carlos
dc.contributor.authorBenavent, Marta
dc.contributor.authorGomez Izquierdo, Lourdes
dc.contributor.authorFierro Fernández, Marta
dc.contributor.authorMorales Burgo, Patricia
dc.contributor.authorJimenez Fonseca, Paula
dc.contributor.authorAnton Pascual, Beatriz
dc.contributor.authorRodríguez Gil, Yolanda
dc.contributor.authorTeijo Quintans, Ana
dc.contributor.authorLa Salvia, Anna
dc.contributor.authorRubio Cuesta, Beatriz
dc.contributor.authorRiesco Martínez, Maria C.
dc.contributor.authorGarcía Carbonero, Rocío
dc.date.accessioned2025-07-29T10:35:49Z
dc.date.available2025-07-29T10:35:49Z
dc.date.issued2023-03
dc.descriptionAcknowledgements: BS is funded by the AECC (POSTDO46SOLD, Spain). AL-P is funded by the Instituto de Salud Carlos III (PFIS; FI20/00131). ALS is funded by the Instituto de Salud Carlos III (Contrato Rio Hortega). CC-P was partially funded by CAM (PEJD-2016-PRE/BMD-2666). BR-C was partially funded by CAM (PEJD-2017-PRE/BMD-4981). MCR-M is funded by the AECC (CLSEN19003RIES). SM-P was supported by the Consejería de Salud y Familias of the Junta de Andalucía through the ‘Nicolás Monardes’ program (RC-0004-2020).
dc.description.abstractNeuroendocrine neoplasms (NENs) are mutationally quiet (low number of mutations/Mb), and epigenetic mechanisms drive their development and progression. We aimed at comprehensively characterising the microRNA (miRNA) profile of NENs, and exploring downstream targets and their epigenetic modulation. In total, 84 cancer-related miRNAs were analysed in 85 NEN samples from lung and gastroenteropancreatic (GEP) origin, and their prognostic value was evaluated by univariate and multivariate models. Transcriptomics (N = 63) and methylomics (N = 30) were performed to predict miRNA target genes, signalling pathways and regulatory CpG sites. Findings were validated in The Cancer Genome Atlas cohorts and in NEN cell lines. We identified a signature of eight miRNAs that stratified patients in three prognostic groups (5-year survival of 80%, 66% and 36%). Expression of the eight-miRNA gene signature correlated with 71 target genes involved in PI3K–Akt and TNFα–NF-kB signalling. Of these, 28 were associated with survival and validated in silico and in vitro. Finally, we identified five CpG sites involved in the epigenetic regulation of these eight miRNAs. In brief, we identified an 8-miRNA signature able to predict survival of patients with GEP and lung NENs, and identified genes and regulatory mechanisms driving prognosis in NEN patients.
dc.description.departmentDepto. de Genética, Fisiología y Microbiología
dc.description.departmentDepto. de Medicina Legal, Psiquiatría y Patología
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Ciencias Biológicas
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipComunidad de Madrid
dc.description.sponsorshipJunta de Andalucía
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipHospital Universitario Virgen del Rocío
dc.description.sponsorshipInstituto de Biomedicina de Sevilla
dc.description.sponsorshipAsociación Española Contra el Cáncer
dc.description.sponsorshipAlbert Einstein Cancer Center
dc.description.statuspub
dc.identifier.citationSoldevilla, B., Lens-Pardo, A., Espinosa-Olarte, P., Carretero-Puche, C., Molina-Pinelo, S., Robles, C., Benavent, M., Gomez-Izquierdo, L., Fierro-Fernández, M., Morales-Burgo, P., Jimenez-Fonseca, P., Anton-Pascual, B., Rodriguez-Gil, Y., Teijo-Quintans, A., La Salvia, A., Rubio-Cuesta, B., Riesco-Martínez, M.C. and Garcia-Carbonero, R. (2023), MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms. Mol Oncol, 17: 582-597. https://doi.org/10.1002/1878-0261.13393
dc.identifier.doi10.1002/1878-0261.13393
dc.identifier.essn1878-0261
dc.identifier.issn1574-7891
dc.identifier.officialurlhttps://doi.org/10.1002/1878-0261.13393
dc.identifier.relatedurlhttps://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13393
dc.identifier.urihttps://hdl.handle.net/20.500.14352/122850
dc.issue.number4
dc.journal.titleMolecular Oncology
dc.language.isoeng
dc.page.final597
dc.page.initial582
dc.publisherWiley
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu577.2
dc.subject.cdu575.113
dc.subject.cdu616-006.48
dc.subject.keywordmiRNAs
dc.subject.keywordNEN biology
dc.subject.keywordNEN patients
dc.subject.keywordPrognostic impact
dc.subject.ucmBiología molecular (Biología)
dc.subject.ucmGenética médica
dc.subject.ucmOncología
dc.subject.unesco2415 Biología Molecular
dc.subject.unesco3201.02 Genética Clínica
dc.subject.unesco3201.01 Oncología
dc.titleMicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number17
dspace.entity.typePublication
relation.isAuthorOfPublicatione16b97d3-1d02-497f-a12a-91301b7b7514
relation.isAuthorOfPublicatione9e27557-79e5-4161-bbc4-adf486de4e2c
relation.isAuthorOfPublicationa3e10db8-836b-4582-9b84-86b538b02ea1
relation.isAuthorOfPublication.latestForDiscoverye16b97d3-1d02-497f-a12a-91301b7b7514

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
MicroRNA_signature.pdf
Size:
1.34 MB
Format:
Adobe Portable Document Format

Collections